The genome is the total DNA content
present in a cell of an individual organism. Genomics is a sub-segment
of genetics that deals with the study of the sequencing and analysis of
an organism’s genome. Clinical genomics specifically deals with the
study of an organism’s genetic make-up for medical purposes such as
prognosis or diagnosis of a disease, determination of pre-existing
causes of a probable disease, and customization of treatment regime as
per the patient’s need. Growth of molecular biology has transformed the
diagnosis and treatment of diseases. Modern test methods, based on the
detection of DNA and RNA, offer several advantages over traditional
methods for the detection of diseases. The new procedures can detect
viruses, bacteria, and genetic variations faster and much more
accurately.
Report Overview @ https://www.transparencymarketresearch.com/clinical-genomics-market.html
Continuous innovation in clinical
genomics has led to personalized health care for better treatment plans
for patients. Genetic sequencing provides various types of technologies
for diagnosis of genetic disorders, some of the prominent technology are
RT-PCR, microarray sequencing, and next generation sequencing.
Availability of a wide range of technologies for diagnosis of disease
presents several choices depending upon cost of test, capability, and
other parameters. This is likely to drive the global clinical genomics
market during the forecast period. Comparative genomic hybridization
(CGH) or chromosomal microarray analysis (CMA) is a method of detecting
copy number variations. It is considered to be an emerging technology
that finds usage in the detection of both chromosomal disorders and
solid tumors. Array comparative genomic hybridization (aCGH) is an
advanced CGH technique that is emerging as a preferred choice over other
traditional techniques due to advancements in terms of workflow and
cost effectiveness. The technology is expected to replace existing
traditional banding techniques and positively impact the growth of the
clinical genomics market. According to the World Health Organization
(WHO), cancer accounts for 8.3 million deaths each year, with 70% new
cancer cases expected to be reported in the next 20 years. Each cancer
type requires unique treatment. Hence, rise in prevalence of cancer and
the need of personalized medicine are expected to drive demand for
clinical genomics during the forecast period. This is likely to provide
significant opportunities for players in the clinical genomics market,
as it is still in a nascent stage.
The global clinical genomics market can
be segmented based on product type, application, end-user, and region.
In terms of product type, the market can be divided into instruments,
consumables & reagents, and services. Based on application, the
global clinical genomics market can be classified into diagnostics,
newborn screening, genetics, carrier screening, and prenatal screening.
In terms of end-user, the market can be categorized into hospitals,
clinics, and diagnostic laboratories. Hospitals and diagnostic
laboratories are anticipated to be the major segments of the clinical
genomics market during the forecast period.
In terms of region, the global clinical
genomics market can be segmented into North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa. North America and
Europe are projected to be the dominant markets for clinical genomics
due to high health care expenditure, and high awareness and acceptance
of novel diagnostic methods. Changing demographics in emerging economies
such as China, India, Brazil, and South Africa are expected to present
high growth opportunities in the clinical genomics market. Public and
private health care expenditure in these countries is expected to
increase, which in turn is likely to drive the focus of manufacturers to
these markets. Improvement in health care infrastructure and government
reimbursement programs in the developed as well as developing countries
are likely to present opportunities in the global clinical genomics
market in the near future.
Key players in the global clinical
genomics market include Abbott Laboratories, PerkinElmer, Inc., Beckman
Coulter, Inc. (Danaher Corporation), Myriad Genetics, Inc., Illumina,
Inc., Astute Medical, Inc., and Thermo Fisher Scientific, Inc.
No comments:
Post a Comment